Skip to main content
Premium Trial:

Request an Annual Quote

Diagenode and MIT Researchers Partner to Automate ChIP-seq Experiments

Premium

The David H. Koch Institute for Integrative Cancer Research and the BioMicro Center at the Massachusetts Institute of Technology are collaborating with Diagenode to automate assays for ChIP-seq and methyl-seq experiments.

The MIT researchers conducted "extensive tests" of Diagenode's SX-8G IP-Star system to validate its use in automating the design of epigenetic assays and next-gen sequencing library preparation. They are also using the system as a quality control for screening antibodies for ChIP-seq experiments.

Robert Urban, executive director of the Koch Institute, said in a statement that being able to automate customizable epigenetic assay design will support the "growing experimental needs of our oncology research community." In addition, Diagenode's SX-8G IP-Star system has "simplified the quality control of ChIP upfront of our ChIP-seq experiments."

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.